Get the Stockscreener App
1.49
0.67%
-0.01
Ikena Oncology Inc stock is traded at $1.49, with a volume of 67,819.
It is down -0.67% in the last 24 hours and down -6.88% over the past month.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
See More
Previous Close:
$1.50
Open:
$1.51
24h Volume:
67,819
Relative Volume:
0.35
Market Cap:
$71.90M
Revenue:
$9.16M
Net Income/Loss:
$-68.17M
P/E Ratio:
-0.9141
EPS:
-1.63
Net Cash Flow:
$-80.16M
1W Performance:
+2.05%
1M Performance:
-6.88%
6M Performance:
-12.35%
1Y Performance:
+10.37%
1-Day Range:
$1.46
$1.53
1-Week Range:
$1.45
$1.53
52-Week Range:
$1.22
$1.94
Ikena Oncology Inc Stock (IKNA) Company Profile
Name
Ikena Oncology Inc
Sector
Industry
Phone
857-343-8292
Address
50 NORTHERN AVE., BOSTON
Compare IKNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKNA
Ikena Oncology Inc
|
1.49 | 71.90M | 9.16M | -68.17M | -80.16M | -1.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ikena Oncology Inc Stock (IKNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-29-24 | Downgrade | Wedbush | Outperform → Neutral |
| Sep-22-23 | Initiated | Wedbush | Outperform |
| May-04-23 | Resumed | H.C. Wainwright | Buy |
| Dec-23-21 | Initiated | H.C. Wainwright | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Credit Suisse | Outperform |
| Apr-20-21 | Initiated | Jefferies | Buy |
| Apr-20-21 | Initiated | William Blair | Outperform |
View All
Ikena Oncology Inc Stock (IKNA) Latest News
Jane Street Group LLC Sells 18,570 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Geode Capital Management LLC Acquires 14,319 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
How former leaders of a sold-off biotech company landed their drugs again - The Business Journals
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - Scrip
US Penny Stocks To Watch In January 2025 - Simply Wall St
What Direction Does Ikena Oncology Inc (NASDAQ: IKNA) Analysts Think The Company Will Take? - Stocks Register
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade - MSN
Is Amazon a Buy, Sell, or Hold in 2025? - Yahoo! Voices
Ikena Oncology and Inmagene Biopharmaceuticals to Merger - citybiz
Spruce Biosciences Appoints Interim Chief Medical Officer - MSN
Inmagene takes back-door route to Nasdaq listing - The Pharma Letter
Ikena Oncology, Inc. announced that it expects to receive $75 million in funding from a group of investors - Marketscreener.com
Five things you need to know, and a Chrismukkah throwback - The Business Journals
Mitek Systems (NASDAQ:MITK) Rating Increased to Strong-Buy at StockNews.com - Defense World
Helius Medical Technologies, Inc. Announces First PoNS System Sale to VA Healthcare SystemOn December 23, 2024, Helius Medical Technologies, Inc. (NASDAQ:HSDT) disclosed its successful sale of the first Portable Neuromodulation Stimulator (PoNS) - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Purchased by Fmr LLC - Defense World
What is HC Wainwright’s Forecast for CVE:NDA Q1 Earnings? - Defense World
Ikena Oncology Enters into Merger Agreement with Inmagene BiopharmaceuticalsOn December 23, 2024, Ikena Oncology, Inc. (NASDAQ: IKNA) announced a significant development as it entered into a Merger Agreement with Inmagene Biopharmaceuticals. - Defense World
**FibroBiologics Enters Standby Equity Purchase Agreement for $25 Million Financing** ** - Defense World
Moving iMage Technologies Reports Results of Annual Meeting On December 19, 2024, Moving iMage Technologies, Inc. (NYSEAMERICAN: MITQ) held its annual meeting of stockholders. The company disclosed details regarding the meeting through an 8-K - Defense World
D-Wave Quantum Inc. (NYSE:QBTS) Receives $5.63 Consensus Price Target from Analysts - Defense World
Salesforce (NYSE:CRM) Stock Price Down 0% Following Insider Selling - Defense World
Boston biotech opts for reverse merger with San Diego company - The Business Journals
Ikena Oncology and Inmagene Announce Merger and Fundraising - Yahoo Finance
Ikena Oncology (NASDAQ:IKNA) Receives “Neutral” Rating from Wedbush - Defense World
Ikena Oncology, Inc. announced that it expects to receive $75 million in funding - Marketscreener.com
Ikena Oncology's (IKNA) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat
Ikena Oncology Merger with Inmagene Biopharmaceuticals and Private Placement Financing - Leerink Partners
Ikena Oncology Shares Rise After Merger Announcement With Inmagene Biopharmaceuticals - MarketWatch
Ikena Oncology and Inmagene Biopharmaceuticals announces merger - MSN
Ikena Oncology, Inmagene Biopharmaceuticals to Merge - MarketWatch
Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis - The Manila Times
iKena Oncology, Inmagene enter definitive merger agreement, private placement - TipRanks
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement - GlobeNewswire
Questor Technology (OTCMKTS:QUTIF) Trading Down 13% – Should You Sell? - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Update - MarketBeat
How Is Procter & Gamble's Stock Performance Compared to Other Consumer Staples Stocks? - MSN
Ikena Oncology FY2024 EPS Estimate Boosted by HC Wainwright - Defense World
Ikena Oncology FY2024 EPS Forecast Lifted by HC Wainwright - MarketBeat
3 US Penny Stocks With Market Caps Over $40M To Consider - Simply Wall St
Ikena Oncology (NASDAQ:IKNA) Earns “Buy” Rating from HC Wainwright - Defense World
Ikena Oncology (NASDAQ:IKNA) Given "Buy" Rating at HC Wainwright - MarketBeat
Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023) - Yahoo Finance
Wedbush Reaffirms “Neutral” Rating for Ikena Oncology (NASDAQ:IKNA) - Defense World
Ikena Oncology Reports Strategic Realignment and Financial Performance - TipRanks
Ikena Oncology Reports Third Quarter 2024 Financial Results - GlobeNewswire
Ikena Oncology Reports 41% Lower Net Loss, Strong $138M Cash Position in Q3 | IKNA Stock News - StockTitan
Halcones signs binding deal to buy Chilean gold project - Yahoo News
Renaissance Technologies LLC Sells 300,200 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals - Indian Pharma Post
Point72 Asia Singapore Pte. Ltd. Invests $75,000 in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Ikena Oncology Inc Stock (IKNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):